

Lupin Appoints Dr. Maurice Chagnaud as President-Europe & Head of Inhalation Strategy

Mumbai, Baltimore, February 18, 2014: Pharma major Lupin, today announced the appointment of Dr. Maurice Chagnaud as its President, Europe and Head of Inhalation Strategy. He will be based at Schaffhausen, Switzerland. Dr. Chagnaud has over 20 years of experience in Pharmaceutical business in Europe having worked with Teva and Merck Generics. He joins Lupin from Israeli drug major, Teva, where he was the Senior Vice President, Central & Eastern Europe, responsible for revenues in excess of over 1 Billion Euros.

In his new role at Lupin, Dr. Chagnaud will assume full responsibility for the Company's European business including the company strategy for Generics & Specialty business in Western and CEE region including Russia & CIS countries. He will also be responsible for developing Lupin's core strategy for Inhalation in the developed markets.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin Limited said, *"Over the years, Lupin has recorded consistent growth across advanced markets like the US and Japan. With Maurice's rich experience we look forward to building our business in Europe, in particular around Complex generics & Specialty. We are delighted to welcome him into the Lupin family."*

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by revenues. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit <http://www.lupinworld.com> for more information.

For further information or queries please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com

Or

Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Alpesh Dalal
Head – M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511
Email: alpeshdalal@lupinpharma.com

[Safe Harbor Statement](#)